WO2014165818A3 - Compositions and methods for preventing and treating prostate cancer - Google Patents

Compositions and methods for preventing and treating prostate cancer Download PDF

Info

Publication number
WO2014165818A3
WO2014165818A3 PCT/US2014/033068 US2014033068W WO2014165818A3 WO 2014165818 A3 WO2014165818 A3 WO 2014165818A3 US 2014033068 W US2014033068 W US 2014033068W WO 2014165818 A3 WO2014165818 A3 WO 2014165818A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostate cancer
methods
compositions
bispecific binding
kits
Prior art date
Application number
PCT/US2014/033068
Other languages
French (fr)
Other versions
WO2014165818A2 (en
Inventor
Markus D. Lacher
Original Assignee
T Cell Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T Cell Therapeutics, Inc. filed Critical T Cell Therapeutics, Inc.
Publication of WO2014165818A2 publication Critical patent/WO2014165818A2/en
Publication of WO2014165818A3 publication Critical patent/WO2014165818A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

Compositions, methods, and kits are provided for treating or preventing prostate cancer. In certain aspects, the compositions, methods, and kits are designed to kill prostate cancer cells. The compositions, methods, and kits can be useful to prevent or treat metastatic prostate cancer. The present invention provides a bispecific binding reagent comprising at least a first domain and a second domain, wherein the first domain specifically binds to a prostate cancer cell surface antigen, and wherein the second domain specifically binds to a T cell surface antigen. The bispecific binding reagent can be used to stimulate immune cell activity against the prostate cancer cell. In certain aspects, the present invention provides a plurality of bispecific binding reagents for co-stimulation of immune cells. Methods for preventing and/or treating metastatic prostate cancer in a subject in need thereof using one or more bispecific binding reagents of the present invention are also provided. In other aspects, the present invention provides isolated nucleic acids, vectors, processes of production, pharmaceutical compositions, and kits related to the bispecific binding reagents described herein. Exemplified are TCTOOl against STEAP1 and CD3E and TCT002 against EpCam and CD28, as well as the combination of the two.
PCT/US2014/033068 2013-04-05 2014-04-04 Compositions and methods for preventing and treating prostate cancer WO2014165818A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361809205P 2013-04-05 2013-04-05
US61/809,205 2013-04-05

Publications (2)

Publication Number Publication Date
WO2014165818A2 WO2014165818A2 (en) 2014-10-09
WO2014165818A3 true WO2014165818A3 (en) 2015-04-23

Family

ID=50846905

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/033068 WO2014165818A2 (en) 2013-04-05 2014-04-04 Compositions and methods for preventing and treating prostate cancer

Country Status (1)

Country Link
WO (1) WO2014165818A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7196094B2 (en) 2017-03-29 2022-12-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Bispecific Antigen Binding Molecules for Costimulatory TNF Receptors

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2647707T1 (en) 2010-11-30 2018-12-31 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
WO2015156268A1 (en) * 2014-04-07 2015-10-15 中外製薬株式会社 Immunoactivating antigen-binding molecule
BR112016026299A2 (en) 2014-05-13 2018-02-20 Chugai Seiyaku Kabushiki Kaisha The T-lymph cell redirection antigen joint molecule to the cell which has an immunosuppressive function
CN107949574A (en) * 2015-10-02 2018-04-20 豪夫迈·罗氏有限公司 Bispecific T cell activation antigen binding molecules
CN108367071B (en) * 2015-11-13 2022-05-13 达纳-法伯癌症研究所有限公司 NKG2D-IG fusion protein for cancer immunotherapy
JP6931329B2 (en) 2015-11-18 2021-09-01 中外製薬株式会社 Combination therapy using T cell redirection antigen-binding molecule for cells with immunosuppressive function
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
CA3005110A1 (en) * 2015-12-17 2017-06-22 Institut National De La Sante Et De La Recherche Medicale Use of antisense long non-coding rnas for the diagnosis of prostate cancer
CN109071626A (en) 2016-02-24 2018-12-21 阿罗姆斯公司 For detecting smell, fragrance and the biosensor of taste
CN106632681B (en) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 Anti- EGFR and AntiCD3 McAb bispecific antibody and its application
CN108264560B (en) * 2016-12-30 2021-08-10 惠和生物技术(上海)有限公司 Bifunctional molecule combining CD3 and CD28 and application thereof
MX2019009468A (en) 2017-02-08 2020-01-20 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer.
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
BR112019018767A2 (en) 2017-04-03 2020-05-05 Hoffmann La Roche antibodies, bispecific antigen binding molecule, one or more isolated polynucleotides, one or more vectors, host cell, method for producing an antibody, pharmaceutical composition, uses, method for treating a disease in an individual and invention
US10209239B1 (en) * 2017-08-16 2019-02-19 Aromyx Corporation Method of making an aromagraph comprising ectopic olfactory receptors
JP2021512630A (en) 2018-02-08 2021-05-20 ドラゴンフライ セラピューティクス， インコーポレイテッド Antibody variable domain targeting NKG2D receptor
CN112584859A (en) * 2018-07-02 2021-03-30 美国安进公司 anti-STEAP 1 antigen binding proteins
CN112771080A (en) * 2018-07-18 2021-05-07 美国安进公司 Chimeric receptors to STEAP1 and methods of use thereof
CA3126707A1 (en) * 2019-01-29 2020-08-06 Gritstone Bio, Inc. Multispecific binding proteins
WO2021207647A1 (en) * 2020-04-09 2021-10-14 Computational International LLC Small molecule drugs as targeted therapeutics
KR20230166150A (en) 2020-08-19 2023-12-06 젠코어 인코포레이티드 Anti-cd28 compositions
US20230406961A1 (en) * 2020-11-03 2023-12-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies
CN112961251B (en) * 2021-03-26 2022-04-29 苏州近岸蛋白质科技股份有限公司 Preparation method and application of CD3 antigen
AR126009A1 (en) * 2021-06-02 2023-08-30 Hoffmann La Roche CD28 ANTIGEN-BINDING AGONIST MOLECULES THAT TARGET EPCAM
WO2023154890A2 (en) * 2022-02-11 2023-08-17 Fred Hutchinson Cancer Center Chimeric antigen receptors binding steap1
WO2023161457A1 (en) 2022-02-27 2023-08-31 Evobright Gmbh Bispecific antibodies against cd277 and a tumor-antigen
WO2024020564A1 (en) * 2022-07-22 2024-01-25 Genentech, Inc. Anti-steap1 antigen-binding molecules and uses thereof
WO2024052831A1 (en) * 2022-09-09 2024-03-14 Janssen Biotech, Inc. Method of treating cancer with an anti tmeff2xcd3 bispecific antibody

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6008031A (en) 1989-05-12 1999-12-28 Duke University Method of analysis and manipulation of DNA utilizing mismatch repair systems
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (en) 1990-08-29 1997-12-16 Genpharm Int PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
JP2000501615A (en) 1995-12-15 2000-02-15 アマーシャム・ライフ・サイエンス・インコーポレーテッド Method using a mismatch repair system for detection and removal of mutant sequences generated during enzyme amplification
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6110668A (en) 1996-10-07 2000-08-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Gene synthesis method
DK1500329T3 (en) 1996-12-03 2012-07-09 Amgen Fremont Inc Human antibodies that specifically bind TNF-alpha
CA2395053C (en) 1999-12-06 2012-05-29 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
CN100374162C (en) 2000-11-06 2008-03-12 法马马有限公司 Effective antitumour treatments
DE10156482A1 (en) 2001-11-12 2003-05-28 Gundram Jung Bispecific antibody molecule
US8053191B2 (en) 2006-08-31 2011-11-08 Westend Asset Clearinghouse Company, Llc Iterative nucleic acid assembly using activation of vector-encoded traits
US8436147B2 (en) 2006-10-27 2013-05-07 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
WO2009070642A1 (en) 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FRIEDRICH MATTHIAS ET AL: "Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens", MOLECULAR CANCER THERAPEUTICS, vol. 11, no. 12, December 2012 (2012-12-01), pages 2664 - 2673, XP002729091, ISSN: 1535-7163 *
HO LYE LIN ET AL: "Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer", PROSTATE, WILEY-LISS, NEW YORK, NY, US, vol. 68, no. 13, 1 September 2008 (2008-09-01), pages 1421 - 1429, XP008101316, ISSN: 0270-4137, [retrieved on 20080709], DOI: 10.1002/PROS.20809 *
RAVINDRANATH MEPUR H ET AL: "Endogenous immune response to gangliosides in patients with confined prostate cancer", INTERNATIONAL JOURNAL OF CANCER, vol. 116, no. 3, September 2005 (2005-09-01), pages 368 - 377, XP002729092, ISSN: 0020-7136 *
RUF PETER ET AL: "Two new trifunctional antibodies for the therapy of human malignant melanoma", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, vol. 108, no. 5, 20 February 2004 (2004-02-20), pages 725 - 732, XP002579122, ISSN: 0020-7136, [retrieved on 20031113], DOI: 10.1002/IJC.11630 *
TAGAWA SCOTT T ET AL: "ANTI-PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)-BASED RADIOIMMUNOTHERAPY FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): A DECADE OF EXPERIENCE WITH RADIOLABELED (RL)-J591", JOURNAL OF UROLOGY, vol. 187, no. 4, Suppl. S, April 2012 (2012-04-01), & ANNUAL MEETING OF THE AMERICAN-UROLOGICAL-ASSOCIATION (AUA); ATLANTA, GA, USA; MAY 19 -23, 2012, pages E387 - E388, XP002729094 *
WU LISA Y ET AL: "Chemoaffinity capture of pre-targeted prostate cancer cells with magnetic beads", PROSTATE, vol. 72, no. 14, October 2012 (2012-10-01), pages 1532 - 1541, XP002729093 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7196094B2 (en) 2017-03-29 2022-12-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Bispecific Antigen Binding Molecules for Costimulatory TNF Receptors

Also Published As

Publication number Publication date
WO2014165818A2 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
WO2014165818A3 (en) Compositions and methods for preventing and treating prostate cancer
MX2020005463A (en) Cd47 antibodies and uses thereof for treating cancer.
WO2015112805A8 (en) Human antibodies to pd-l1
MX2018006973A (en) Humanized anti-cd73 antibodies.
MX2022015823A (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof.
ZA201707869B (en) Anti-ntb-a antibodies and related compositions and methods
PH12017501166A1 (en) Antibodies to tight
MX2020006668A (en) Antibodies to lilrb2.
MX2017004691A (en) Cd73 blockade.
NZ739252A (en) Monoclonal antibodies against bcma
MX2019008065A (en) Compositions comprising anti-cd38 antibodies and lenalidomide.
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2013063186A3 (en) Monoclonal antibodies and methods of use
MX357391B (en) Anti-erbb3 antibodies and uses thereof.
PH12015502126A1 (en) Human pac1 antibodies
BR112014019579A2 (en) SINGLE CHAIN ANTIBODY, POLYNUCLEOTIDE, VECTOR, HOST CELL, METHOD OF PRODUCTION OF A SINGLE CHAIN ANTIBODY, HETEROMULTYMER AND METHOD OF PRODUCTION
WO2017136659A3 (en) Humanized anti-cd3 antibodies, conjugates and uses thereof
PH12015502112A1 (en) Cancer treatment using antibodies that bind cell surface grp78
MY184628A (en) Afucosylated anti-fgfr2iiib antibodies
NZ595641A (en) Humanized anti-egfl7 antibodies and methods using same
WO2016160618A3 (en) Car t-cell therapy directed to lhr for the treatment of solid tumors
MX2016004304A (en) Conjugated antibodies against ly75 for the treatment of cancer.
WO2016164743A3 (en) Cd38 ligand-drug conjugates for targeted cancer therapy
WO2014153209A8 (en) Antisense oligonucleotides for treatment of cancer stem cells
WO2017079273A3 (en) Antibodies for targeting cancer stem cells and treating aggressive cancers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14727378

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14727378

Country of ref document: EP

Kind code of ref document: A2